The (patho)physiology of megakaryocytopoiesis: From thrombopoietin in diagnostics and therapy to ex vivo generated cellular products

Vox Sanguinis, Supplement

Volumn 87, Issue 2, 2004, Pages

  Tijssen, M R ^a   Van Der Schoot, C E ^a   Voermans, C ^a   Zwaginga, J J ^a  

^a SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MPL PROTEIN; NONTHROMBOPOIETIN MPL AGONIST; PROTEIN; RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; UNCLASSIFIED DRUG;

BONE MARROW BIOPSY; CONFERENCE PAPER; CRYOPRESERVATION; DIAGNOSTIC TEST; DRUG ACTIVITY; EX VIVO STUDY; GENE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOGENICITY; IN VITRO STUDY; LIFESPAN; MEGAKARYOCYTE; MEGAKARYOPOIESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE COUNT; THROMBOCYTE PRESERVATION; TPO GENE;

ANIMALS; BLOOD PLATELETS; BONE MARROW CELLS; CELL DIFFERENTIATION; HUMANS; MEGAKARYOCYTES; MICE; MICE, INBRED NOD; MICE, SCID; PROTEIN STRUCTURE, TERTIARY; THROMBOPOIESIS; THROMBOPOIETIN; UP-REGULATION;

EID: 4444355389     PISSN: 17416892     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Kaushansky K, Drachman JG: The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 2002; 21:3359-3367
2. Vigon I, Momon JP, Cocault L, Mitjavila MT, Tambourin P, Gisselbrecht S, Souyri M: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor super-family. Proc Natl Acad Sci USA 1992; 89:5640-5644
3. Methia N, Louache F, Vainchenker W, Wendung F: Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood 1993; 82:1395-1401
4. Alexander WS: Thrombopoietin and the c-Mpl receptor: insights from gene targeting. Int J Biochem Cell Biol 1999; 31:1027-1035
5. Drayer L, Boer A-K, Esselink M, Vellenga E: Synergistic STAT5 transactivation by SCF and TPO in megakaryocytic MO7e cells [abstract]. Blood 2003; 102:836a
6. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, Jin DK, Dias S, Zhang F, Hartman TE, Hackett NR, Crystal RG, Witte L, Hicklin DJ, Bohlen P, Eaton D, Lyden D, De Sauvage F, Rafii S: Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10:64-71
7. Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N, Zucker-Franklin D, Lofton-Day C: Thrombopoietin, the Mp 1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92:3234-3238
8. Sungaran R, Markovic B, Chong BH: Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997; 89:101-107
9. Nomura S, Ogami K, Kawamura K, Tsukamoto I, Kudo Y, Kanakura Y, Kitamura Y, Miyazaki H, Kato T: Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol 1997; 25:565-572
10. Linthorst GE, Folman CC, van Olden RW, von dem Borne AE: Plasma thrombopoietin levels in patients with chronic renal failure. Hematol J 2002; 3:38-42
11. Folman CC, von dem Borne AE, Rensink IH, Gerritsen W, van der Schoot CE, de Haas M, Aarden L: Sensitive measurement of thrombopoietin by a monoclonal antibody based sandwich enzyme-linked immunosorbent assay. Thromb Haemost 1997; 78:1262-1267
12. Folman CC, de Jong SM, de Haas M, von dem Borne AE: Analysis of the kinetics of TPO uptake during platelet transfusion. Transfusion 2001; 41:517-521
13. Porelijn L, Folman CC, Bossers B, Huiskes E, Overbeeke MA, Schoot CE, de Haas M, von dem Borne AE: The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998; 79:1101-1105
14. Engel C, Loeffler M, Franke H, Schmitz S: Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br J Haematol 1999; 105:832-838
15. Konishi H, Ochiya T, Yasuda Y, Sakamoto H, Muto T, Sugimura T, Terada M: HST-1/FGF-4 stimulates proliferation of megakaryocyte progenitors synergistically and promotes megakaryocyte maturation. Oncogene 1996; 13:9-19
16. Folman CC, Ooms M, Kuenen BB, de Jong SM, Vet RJ, de Haas M, von dem Borne AE: The role of thrombopoietin in post-operative thrombocytosis. Br J Haematol 2001; 114:126-133
17. Werynska B, Ramlau R, Podolak-Dawidziak M, Jankowska R, Prajs I, Usnarska-Zubkiewicz L, Kuliczkowski K: Serum thrombopoietin levels in patients with reactive thrombocytosis due to lung cancer and in patients with essential thrombocythemia. Neoplasma 2003; 50:447-451
18. Kaushansky K: Etiology of the myeloproliferative disorders: the role of thrombopoietin. Semin Hematol 2003; 40:6-9
19. van den Oudenrijn S, Bruin M, Folman CC, Bussel J, de Haas M, von dem Borne AE: Three parameters, plasma thrombopoietin levels, plasma glycocalicin levels and megakaryocyte culture, distinguish between different causes of congenital thrombocytopenia. Br J Haematol 2002; 117:390-398
20. Germeshausen M, Ballmaier M, Weite K: Implications of mutations in hematopoietic growth factor receptor genes in congenital cytopenias. Ann N Y Acad Sci 2001; 938:305-320
21. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, Krukemeier S, Eilers M, Strauss G, Weite K: c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001; 97:139-146
22. van den Oudenrijn S, Bruin M, Folman CC, Peters M, Faulkner LB, de Haas M, von dem Borne AE: Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br J Haematol 2000; 110:441-448
23. Escoffre-Barbe M, Beaucornu P, Dauriac C, Amiot L, Bernard M, Fauchet R, Lamy T, Fardel O: Advantage of CFU-MK cultures using a serum-free collagen method for the biological exploration of Essential Thrombocythemia and Polycythemia Vera [abstract]. Blood 2003; 102:340b
24. Debili N, Coulombel L, Croisille L, Katz A, Guichard J, Breton-Gorius J, Vainchenker W: Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood 1996; 88:1284-1296
25. Kuter DJ, Begley CG: Recombinant human thrombopoietin, basic biology and evaluation of clinical studies. Blood 2002; 100:3457-3469
26. Vadhan-Raj S, Kavanagh JJ, Freedman RS, Folloder J, Currie LM, Bueso-Ramos C, Verschraegen CF, Narvios AB, Connor J, Hoots WK, Broemeling LD, Lichtiger B: Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study. Lancet 2002; 359:2145-2152
27. Van Os E, Wu YP, Pouwels JG, Ijsseldijk MJ, Sixma JJ, Akkerman JW, De Groot PG, van Willigen G: Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br J Haematol 2003; 121:482-490
28. Bussel JB, George JN, Kuter DJ, Wasser JS, Aledort LM, Chen MG, Nichol JL: An open-label, dose-finding study evaluating the safety and platelet response of a novel thrombopoietic protein (AMG 531) in thrombocytopenic adult patients with Immune Thromobcytopenic Purpura (FTP) [abstract]. Blood 2003; 102:86a
29. Nash RA, Kurzrock R, DiPersio J, Vose J, Linker C, Maharaj D, Nademanee AP, Negrin R, Nimer S, Shulman H, Ashby M, Jones D, Appelbaum FR, Champlin R: A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2000; 6:25-34
30. Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, Sanz MA, Heil G, Fenaux P, Brugger W, Barge A, O'Brien-Ewen C, Matcham J, Hoelzer D: A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94:3694-3701
31. Vadhan-Raj S, Patel S, Bueso-Ramos C, Folloder J, Papadopolous N, Burgess A, Broemeling LD, Broxmeyer HE, Benjamin RS: Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol 2003; 21:3158-3167
32. + cells measured under conditions that prevent P-selectin-mediated binding of platelets. Blood 1995; 86:3771-3782
33. Ratajczak MZ, Ratajczak J, Machalinski B, Mick R, Gewirtz AM: In vitro and in vivo evidence that ex vivo cytokine priming of donor marrow cells may ameliorate posttransplant thrombocytopenia. Blood 1998; 91:353-359
34. Bruno S, Gunetti M, Gammaitoni L, Dane A, Cavalloni G, Sanavio F, Fagioli F, Aglietta M, Piacibello W: In vitro and in vivo megakaryocyte differentiation of fresh and ex-vivo expanded cord blood cells: rapid and transient megakaryocyte reconstitution. Haematologica 2003; 88:379-387
35. Bertolini F, Battaglia M, Pedrazzoli P, Da Prada GA, Lanza A, Soligo D, Caneva L, Sarina B, Murphy S, Thomas T: della Cuna GR: Megakaryocytic progenitors can be generated ex vivo and safely administered to autologous peripheral blood progenitor cell transplant recipients. Blood 1997; 89:2679-2688
36. van den Oudenrijn de Haas M, Calafat J, van der School CE, dem Borne AE: A combination of megakaryocyte growth and development factor and interleukin-1 is sufficient to culture large numbers of megakaryocytic progenitors and megakaryocytes for transfusion purposes. Br J Haematol 1999; 106:553-563
37. Drayer AL, Smit Sibinga CT, Esselink MT, De Wolf JT, Vellenga E: In vitro megakaryocyte expansion in patients with delayed platelet engraftment after autologous stem cell transplantation. Ann Hematol 2002; 81:192-197
38. Kirito K, Fox N, Kaushansky K: Thrombopoietin stimulates Hoxb4 expression. an explanation for the favorable effects of TPO on hematopoietic stem cells. Blood 2003; 102:3172-3178
39. Amsellem S, Pflumio F, Bardinet D, Izac B, Chameau P, Romeo PH, Dubart-Kupperschmitt A, Fichelson S: Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat Med 2003; 9:1423-1427
40. Krosl J, Austin P, Beslu N, Kroon E, Humphries RK, Sauvageau G: In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat Med 2003; 9:1428-1432